Related Experiment Video
Updated: Feb 28, 2026
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
Published on: November 29, 2024
Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?
Muhammad Abdul-Ghani1,2, Ralph A DeFronzo3, Stefano Del Prato4
1Division of Diabetes, University of Texas Health Science Center at San Antonio, and South Texas Veterans Health Care System, San Antonio, TX albarado@uthscsa.edu.
Insights
Newer diabetes drugs like liraglutide and semaglutide show cardiovascular benefits beyond glucose control. Combining these agents may offer additive or multiplicative reductions in cardiovascular events for type 2 diabetes patients.
Area of Science:
- Cardiology
- Endocrinology
- Pharmacology
Background:
- Hyperglycemia in type 2 diabetes (T2D) primarily causes microvascular issues, but cardiovascular disease (CVD) remains the leading cause of mortality.
- Standard glycemic control (HbA1c) offers limited CVD risk reduction.
- Recent trials highlight CVD benefits of specific antidiabetes agents beyond glucose lowering.
Purpose of the Study:
- To analyze the cardiovascular benefits of glucagon-like peptide 1 receptor agonists (liraglutide, semaglutide) and other antidiabetes agents (empagliflozin, pioglitazone) in T2D patients.
- To explore potential additive or multiplicative cardiovascular benefits from combining these agents due to differing mechanisms of action.
Main Methods:
- Review of major clinical trials including LEADER, SUSTAIN-6, EMPA-REG OUTCOME, IRIS, and PROactive.
- Comparative analysis of the effects of liraglutide, semaglutide, empagliflozin, and pioglitazone on major adverse cardiac events (MACE) and their individual components.
Main Results:
- Liraglutide and semaglutide significantly reduced MACE by 13% and 24% respectively in high-CVD-risk T2D patients.
- Empagliflozin and pioglitazone also demonstrated significant cardiovascular event reduction in T2D.
- Observed differences in the impact on individual MACE components suggest distinct underlying mechanisms for cardiovascular risk reduction.
Conclusions:
- While multiple antidiabetes agents lower glucose, their cardiovascular benefits appear mediated by diverse mechanisms.
- The distinct pathways suggest that combining agents like liraglutide, semaglutide, empagliflozin, and pioglitazone could yield synergistic cardiovascular protection in T2D.
Abstract:
Hyperglycemia is the major risk factor for microvascular complications in patients with type 2 diabetes (T2D). However, cardiovascular disease (CVD) is the principal cause of death, and lowering HbA1c has only a modest effect on reducing CVD risk and mortality. The recently published LEADER and SUSTAIN-6 trials demonstrate that, in T2D patients with high CVD risk, the glucagon-like peptide 1 receptor agonists liraglutide and semaglutide reduce the primary major adverse cardiac events (MACE) end point (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) by 13% and 24%, respectively. The EMPA-REG OUTCOME, IRIS (subjects without diabetes), and PROactive (second principal end point) studies also demonstrated a significant reduction in cardiovascular events in T2D patients treated with empagliflozin and pioglitazone. However, the benefit of these four antidiabetes agents (liraglutide, semaglutide, empagliflozin, and pioglitazone) on the three individual MACE end points differed, suggesting that different underlying mechanisms were responsible for the reduction in cardiovascular events. Since liraglutide, semaglutide, pioglitazone, and empagliflozin similarly lower the plasma glucose concentration but appear to reduce CVD risk by different mechanisms, there emerges the intriguing possibility that, if used in combination, the effects of these antidiabetes agents may be additive or even multiplicative with regard to cardiovascular benefit.
More Related Videos
07:22Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
Published on: March 7, 2025
07:51Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
Published on: September 26, 2018
Related Concept Videos
01:22Diabetes Mellitus: Type 2 and Gestational
01:36Carbohydrate Metabolism
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
01:30Coronary Artery Disease I: Introduction
01:20Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
01:22Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:19Psychoneuroimmunology: Diabetes and Cancer